Trial Profile
Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2017 New trial record